Get the Stockscreener App
0.739
5.00%
0.0352
Pre-market:
.75
0.011
+1.49%
Affimed N V stock is traded at $0.739, with a volume of 76,833.
It is up +5.00% in the last 24 hours and down -16.79% over the past month.
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The Company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.
See More
Previous Close:
$0.7038
Open:
$0.74
24h Volume:
76,833
Relative Volume:
0.65
Market Cap:
$11.82M
Revenue:
$19.91M
Net Income/Loss:
$-127.11M
P/E Ratio:
-0.0877
EPS:
-8.428
Net Cash Flow:
$-132.44M
1W Performance:
+2.50%
1M Performance:
-16.79%
6M Performance:
-78.76%
1Y Performance:
-85.22%
1-Day Range:
$0.7001
$0.7549
1-Week Range:
$0.7001
$0.758
52-Week Range:
$0.52
$8.95
Affimed N V Stock (AFMD) Company Profile
Compare AFMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AFMD
Affimed N V
|
0.739 | 11.82M | 19.91M | -127.11M | -132.44M | -8.428 |
|
VRTX
Vertex Pharmaceuticals Inc
|
490.47 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
585.49 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
599.87 | 36.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
236.75 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
252.77 | 25.74B | 3.81B | -644.79M | -669.77M | -6.24 |
Affimed N V Stock (AFMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-22 | Initiated | H.C. Wainwright | Buy |
| Oct-10-22 | Downgrade | Stifel | Buy → Hold |
| Aug-18-22 | Resumed | Wells Fargo | Overweight |
| Mar-31-22 | Initiated | Piper Sandler | Overweight |
| Feb-23-22 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-21-21 | Initiated | Truist | Buy |
| Sep-30-21 | Initiated | Stifel | Buy |
| Mar-31-21 | Initiated | Credit Suisse | Outperform |
| Mar-28-19 | Initiated | SVB Leerink | Outperform |
| Aug-28-18 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-17 | Initiated | SunTrust | Buy |
| Aug-12-16 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| May-19-16 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| Dec-10-15 | Initiated | Laidlaw | Buy |
| Dec-04-15 | Initiated | Wells Fargo | Outperform |
| Sep-09-15 | Initiated | Jefferies | Hold |
| Aug-06-15 | Reiterated | Oppenheimer | Outperform |
| Jun-22-15 | Reiterated | Jefferies | Buy |
View All
Affimed N V Stock (AFMD) Latest News
Affimed faces Nasdaq delisting over share price rule By Investing.com - Investing.com Canada
Affimed Faces Nasdaq Delisting Risk Due to Share Price - TipRanks
Affimed faces Nasdaq delisting over share price rule - Investing.com Australia
Affimed Receives Nasdaq Deficiency Notice Over Low Share Price: Retail’s In Wait-And-Wait Mode - MSN
Affimed (AFMD) Faces Nasdaq Delisting Risk Due to Low Share Price | AFMD Stock News - GuruFocus
Affimed (AFMD) Faces Nasdaq Delisting Risk Over Share Price - GuruFocus
Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement | AFMD Stock News - GuruFocus
Affimed N.V. Receives Nasdaq Notification Regarding Minimum Bid Price Compliance - Nasdaq
Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement - GlobeNewswire
Affimed Gets 180-Day Nasdaq Grace Period After Stock Falls Below $1, Extension Possible - Stock Titan
Affimed (NASDAQ:AFMD) Coverage Initiated at StockNews.com - Defense World
Affimed N.V. Receives EUR 2.4 Million Research Grant from German Government to Fund Trispecific Abs - marketscreener.com
Affimed (NASDAQ:AFMD) Now Covered by Analysts at StockNews.com - Defense World
Affimed (NASDAQ:AFMD) Receives $13.50 Average Target Price from Analysts - Defense World
Short Interest in Affimed (NASDAQ:AFMD) Declines By 14.9% - Defense World
Affimed Announces Acceptance of AFM24 Abstract on Dose - GlobeNewswire
Major Cancer Conference to Showcase New AFM24 Drug Optimization Results for Lung Cancer Treatment - Stock Titan
Affimed (AFMD) to Release Earnings on Thursday - Defense World
Affimed at Leerink’s Conference: Clinical and Strategic Insights - Investing.com
Affimed at Leerink’s Conference: Clinical and Strategic Insights By Investing.com - Investing.com UK
Affimed N.V. to Host Earnings Call - ACCESS Newswire
Can Affimed's CEO Presentation Signal New Oncology Breakthroughs? Conference Watch - StockTitan
Affimed to Present at the Leerink Partners Global Healthcare Conference 2025 - The Manila Times
Affimed Announces Proposed Public Offering Of Common Stock - Reuters
Short Interest in Affimed (NASDAQ:AFMD) Declines By 12.3% - Defense World
Affimed (NASDAQ:AFMD) Stock Passes Below Two Hundred Day Moving Average – Here’s Why - Defense World
Jane Street Group LLC Acquires New Position in Affimed (NASDAQ:AFMD) - Defense World
Affimed (NASDAQ:AFMD) Sees Large Increase in Short Interest - Defense World
HC Wainwright Issues Positive Forecast for Affimed Earnings - Defense World
Equities Analysts Offer Predictions for Affimed Q1 Earnings - Defense World
Affimed Shares Fall 32% on Clinical Update - GuruFocus.com
Affimed stock plunges 23% on AFM24 study update - MSN
Affimed (NASDAQ:AFMD) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Affimed stock plunges 23% on AFM24 study update (AFMD:NASDAQ) - Seeking Alpha
Affimed’s Promising Clinical Update on NSCLC Treatment - TipRanks
Affimed Reports Positive Clinical Update on - GlobeNewswire
Affimed's AFM24 Trial Shows Promising 24% Response Rate in EGFR-Mutant Lung Cancer Patients - StockTitan
Affimed says 86% of patients responded to lymphoma therapy in mid-stage trial - MSN
Wells Fargo & Company Lowers Affimed (NASDAQ:AFMD) Price Target to $15.00 - Defense World
Affimed (NASDAQ:AFMD) Short Interest Update - Defense World
AFMD Stock Down Despite FDA's RMAT Status for Lymphoma Therapy - MSN
Affimed Reports Promising Phase 1 Efficacy and Safety Data - GlobeNewswire
Affimed Reports Promising Phase 1 Efficacy and Safety - One News Page
Affimed to Host Investor Conference Call Highlighting - GlobeNewswire
Affimed to Present AFM24 Lung Cancer Clinical Data in Conference Call - StockTitan
Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) - Yahoo Finance
Affimed's Cancer Drug Achieves 86% Response Rate in Advanced Lymphoma Clinical Trial - StockTitan
Affimed Announces Positive Results Demonstrating Safety and - GlobeNewswire
Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients - Yahoo Finance
Affimed Announces Pricing of Upsized $90 Million Public Offering of Common Shares - StockTitan
Affimed N V Stock (AFMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):